the story of glp 1 Reflections on discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions The GLP-1 Story... (a GoggleDocs

In addition, we discuss the most recent evidence-based indications for revascularisation in patients with diabetes as well as the targets for glycaemic control post revascularisation

Unlike orally delivered chelators, which must survive harsh GI conditions and extensive hepatic first-pass effect before reaching systemic circulation, IN drugs only need to cross the nasal epithelium or can directly access the brain through neuronal pathways

Studies are lacking on the safety and efficacy of GLP-agonists in decompensated NASH cirrhosis

Roll Call In The Oral GLP-1 Race By Katie Anderson, Chief Editor, Pharmaceutical Online The market for GLP-1 agonists is booming and expected to only get bigger

Your Cycle Gives It Away Shorter intervals, longer ones, skipped periods, the whole thing going erratic